International Conference on Reproduction, Pregnancy, and Rheumatic Disease

 描述(申请人提供)：由于风湿病的治疗改善了患者的福祉，患有这些疾病的妇女对怀孕越来越感兴趣。然而，潜在的风湿病增加了母亲和婴儿的健康风险。孕妇面临疾病突发、器官损伤、先兆子痫和死亡的风险。除了高胎儿损失率外，后代还面临着早产和胎儿生长受限带来的长期健康后果的风险。这些风险使得对妊娠期风湿病的适当管理至关重要，但如何最好地做到这一点仍不清楚。本次国际会议将汇聚全球该领域的领军人物，分享 现有数据、临床经验和潜在研究领域。这些交流将有助于制定最终影响患者护理的治疗策略和研究想法。这次为期三天的会议延续了风湿病妊娠领域领先专家举行国际两年一次会议的20年传统。这次会议自2002年以来就没有在美国举行过，将给对这一领域感兴趣的美国供应商一个参与的机会。这次会议将有两个首要目标：1)向该领域的研究人员介绍新的研究成果和研究方法；以及汇集该领域专家的知识和实践，向更广泛的风湿病和产科社区传播信息。一个附带的目标是促进网络建设，以建立协作研究。共享知识的第一个目标将通过一系列简短的讲座和抽象的演讲来实现。最近在美国完成的两项关于风湿病中妊娠的大型研究的结果将被公布，并将讨论这些发现的后果。同时举行的一次会议将集中讨论研究的新方法，以激发新的研究项目，并以具有临床意义和一致的形式组织研究。将特别注意通过介绍摘要和具有挑战性的案例来鼓励受训人员参与。传播会议成果的第二个目标将通过手稿实现。第一个将涉及新的FDA怀孕和哺乳标签规则。这将包括如何解释动物、人类和哺乳期数据的信息，以及系统性红斑狼疮和类风湿性关节炎怀孕背景风险的评估。本文将指导临床医生选择风湿病的治疗方法。第二份手稿将汇编专家在新生儿狼疮先天性心脏传导阻滞(CHB)筛查、预防和管理方面的实践，因为目前这一领域的实践差异很大。这将通过会前问卷调查，然后讨论结果和现有数据并提出摘要建议来完成。最先进的论文将报道具有挑战性的案例和对其管理的意见，以及其他重要的陈述。这次会议将是互动的，提供充足的时间进行交流，并促进专家和受训者之间的合作。它将激励美国在这一领域的努力，并促进未来的协调研究努力。

 DESCRIPTION (provided by applicant): As therapies for rheumatic diseases have improved the well-being of patients, women with these diseases are increasingly interested in pregnancy. However, underlying rheumatologic disease increases the health risks for both mother and baby. Pregnant women are at risk for disease flare, organ damage, preeclampsia, and death. Beyond a high rate of fetal loss, offspring are at risk for long-term health consequences from preterm birth and fetal growth restriction. These risks make appropriate management of rheumatologic disease in pregnancy essential, but how best to manage to do this remains unclear. This international conference will bring together worldwide leaders in this field to share existing data, clinical experience, and areas of potential study. These interchanges will help to formulate treatment strategies and research ideas that will ultimately impact patient care. This three day conference continues the two-decade tradition of international biennial meetings among leading experts in the field of pregnancy in rheumatic diseases. This meeting has not taken place in the U.S. since 2002 and will give US providers interested in this area an opportunity to participate. The conference will have two overarching goals: 1.) to update researchers in this field about new study results and research methods; and 2.) to aggregate the knowledge and practices of experts in this field to disseminate information to the wider rheumatology and obstetrics communities. An adjunct goal is to facilitate networking to build collaborative research. The first goal of sharing knowledge will be met through a series of short lectures and abstract presentations. The results of two large recently-completed U.S.-based studies of pregnancy in rheumatologic disease will be presented and the ramifications of the findings will be discussed. A concurrent session will focus on novel approaches to research, to both inspire new research projects and to structure research in clinically meaningful and aligned formats. Special attention will be made to encourage trainee involvement through presentations of abstracts and challenging cases. The second goal of disseminating the findings of the conference will be accomplished through manuscripts. The first will address the new FDA Pregnancy and Lactation Labeling Rule. This will include information about how to interpret animal, human and lactation data, and an assessment of the background risk of pregnancy from systemic lupus and rheumatoid arthritis. This paper will guide clinicians in choosing rheumatologic therapies. The second manuscript will compile the practices of experts in screening, prevention, and management of congenital heart block (CHB) from neonatal lupus, as current practice in this area is widely variable. This will be accomplished through a pre-meeting questionnaire, followed by a discussion of the results and the existing data with summary recommendations. A State of the Art paper will report challenging cases and opinions on their management, other important presentations. This conference will be interactive, provide ample time for networking, and foster collaboration between experts and trainees. It will galvanize the U.S-based efforts in this field and promote future coordinated research efforts.